We had the pleasure of hosting Dr @ditchhaporia former president of the American College of Cardiology, for grand rounds, where she also offered candid career guidance for fellows @FadiAdelMD@MayoClinicCV@MayoCVFellows
Visualization of the left atrial appendage will never be the same! My #NaughtyFellow found a windsock, a chicken wing, broccoli, and cactus in the LAA space! Transillumination and transparency is the way to go. No need for CT! #EchoFirst
Read more here: onlinejase.com/article/S0894…
Learned that building a procedural niche requires disciplined focus, while maintaining openness to adapt and expand the direction of both clinical practice and research. Thanks Dr Cohen for your time and insights @djc795@MayoClinicCV@crfheart
🎥 Clinical Investigator Career in Interventional Cardiology
Dr. David J. Cohen shares insights on building a career at the intersection of research, innovation, and patient care
▶️ Full interview on YouTube:
youtube.com/watch?v=uf0etWHV…#ACC#FITsOnTheGo@djc795@HamandiMd
FITsOnTheGo is a @MayoClinicCV initiative led by fellows in training, featuring interviews with late-breaking trialists.
Join us at the studio in the #ACC26 Learning Lounge, next to the Heart to Heart stage!
Today, the @MayoCVFellows were privileged to host @MKIttlesonMD as our annual Fellows' Visiting Professor.
It was a day full of clinical gems, intense debate, and #kittlesonrules.
Dr. Kittleson - thank you for joining us, and please come back soon to @MayoClinicCV@MayoClinic
I’m pleased to share that for the 8th consecutive year, Mayo Clinic is ranked the No. 1 hospital in the world by @Newsweek thanks to the extraordinary expertise, compassion, and commitment of our staff. rankings.newsweek.com/worlds…
Contratulations @HamandiMd for this important contribution! MAC with mitral valve dysfunction and tricuspid regurgitation often coexist. It's important to study this as we enter the commercial era for TMVR in MAC with already 1 TMVR device (Tendyne) FDA approved for patients with MAC in 2025. Keep up the good work @MayoClinicCV !
Presented our study on the prognostic impact of tricuspid regurgitation in patients with mitral annular calcification at TCT in San Francisco.
Thanks Dr Guerrero and Dr Pellikka for your mentorship and support.
@MayoClinicCV@MayoCVFellows@MayraGuerreroMD@pattypellikka
Grateful for an incredible experience at #TCT2025 — from presenting our latest research to connecting with mentors and catching up with friends. Huge thanks to @TCTMD@crfheart@MayoClinicCV@MayoCVFellows
Once the forgotten, tricuspid valve is now the center of attention. TR is the most prevalent valvular heart disease among U.S. adults aged 65 to 85 years. #TCT2025#PREVUEVALVE
Presented our study on the prognostic impact of tricuspid regurgitation in patients with mitral annular calcification at TCT in San Francisco.
Thanks Dr Guerrero and Dr Pellikka for your mentorship and support.
@MayoClinicCV@MayoCVFellows@MayraGuerreroMD@pattypellikka